AT1 receptor antagonist Candesartan in selected cirrhotic patients: Effect on portal pressure and liver fibrosis markers

Journal of Hepatology

Volumn 46, Issue 6, 2007, Pages 1026-1033

  Debernardi Venon, Wilma ^a   Martini, Silvia ^a   Biasi, Fiorella ^b   Vizio, Barbara ^b   Termine, Angela ^b   Poli, Giuseppe ^b   Brunello, Franco ^a   Alessandria, Carlo ^a   Bonardi, Renato ^a   Saracco, Giorgio ^a   Rizzetto, Mario ^a   Marzano, Alfredo ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

Hyaluronic acid; Liver fibrosis; Portal hypertension; Portal pressure; Renin angiotensin system

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN; CANDESARTAN HEXETIL; HYALURONIC ACID; PROCOLLAGEN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; LIVER FIBROSIS; MALE; PORTAL HYPERTENSION; PRESSURE GRADIENT; PRIORITY JOURNAL; SEROLOGY; VENOUS PRESSURE;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; FEMALE; FIBROSIS; HUMANS; HYALURONIC ACID; LIVER; MALE; MIDDLE AGED; PORTAL PRESSURE; PROCOLLAGEN; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 34247633516     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2007.01.017     Document Type: Article

References (67)

1. Friedman S.L. Liver fibrosis-from bench to bedside. J Hepatol 38 (2003) S38-S53
2. Pinzani M. Liver fibrosis. Springer Semin Immunopathol 21 (1999) 475-490
3. Bataller R., and Brenner D. Liver fibrosis. J Clin Invest 115 (2005) 209-218
4. Benyon R.C., and Iridale J.P. Is liver fibrosis reversible?. Gut 46 (2000) 443-446
5. Gines P., Cardenas A., Arroyo V., and Rodes J. Management of cirrhosis and ascites. N Engl J Med 350 (2004) 1646-1654
6. Friedman S.L., Roll F.J., Boyles J., and Bissell D.M. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci USA 82 (1985) 8681-8685
7. Geerts A. History, heterogeneity, developmental biology and functions of quiescent hepatic stellate cells. Semin Liver Dis 21 (2001) 311-335
8. Bataller R., Gines P., Nicolas J.M., Go{combining double acute accent}rbig M.N., Garcia-Ramallo E., Gasull X., et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 118 (2000) 1149-1156
9. Bataller R., Sancho-Bru P., Gines P., Lora J.M., Al-Garawi A., Sole' M., et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesise angiotensin II. Gastroenterology 125 (2003) 117-125
10. Friedman S.L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 275 (2000) 2247-2250
11. Bataller R., and Brenner D.A. Activated hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis 21 (2001) 437-451
12. Reynaert H., Thompson M.G., Thomas T., and Geerts A. Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut 50 (2002) 571-581
13. Yoshiji H., Kurijama S., Yoshii J., Ikenada Y., Noguchi R., Nakatani T., et al. Angiotensin II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 34 (2001) 745-750
14. Jonsson J.R., Clouston A.D., Ando Y., Kelemen L.I., Horn M.J., Adamson M.D., et al. Angiotensin - converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 121 (2001) 148-155
15. Paizis G., Gilbert R.E., Cooper M.E., Murthi P., Schembri J.M., Wu L.L., et al. Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J Hepatol 35 (2001) 376-385
16. Wei H.S., Li D.G., Lu H.M., Zhan Y.T., Wang Z.R., Huang X., et al. Effects of AT1 receptor antagonist, Losartan, on rat hepatic fibrosis induced by CCl (4). World J Gastroenterol 6 (2000) 540-545
17. Terui Y., Saito T., Watanabe H., Togashi H., Kawata S., Kamada Y., et al. Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology 36 (2002) 1022
18. Rimola A., Londono M.C., Guevara G., Bruguera M., Navasa M., Forns X., et al. Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplant 78 (2004) 686-691
19. Yokohama S., Yoneda M., Haneda M., Okamoto S., Okada M., Aso K., et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with non-alcoholic steatohepatitis. Hepatology 40 (2004) 1222-1225
20. Sookoian S., Fernandez M.A., and Castaño G. Effects of six months Losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study. World J Gastroenterol 11 (2005) 7560-7563
21. Schneider A.W., Falk J.F., and Klein C.P. Effect of Losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 29 (1999) 334-339
22. Gonzales-Abraldes J., Albillos A., Banares R., Arbol L.R.D., Moitinho E., Rodriguez C., et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 121 (2001) 382-388
23. Schepke M., Werner E.V.A., Biecker E., Schiedermaier P., Heller J., Neef M., et al. Hemodynamic effects of the angiotensin II receptor antagonist Irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology 121 (2001) 389-395
24. Debernardi-Venon W., Baronio M., Leone N., Rolfo E., Fadda M., Barletti C., et al. Effects of long-term Irbesartan in reducing portal pressure in cirrhotic patients: comparison with propranolol in a randomized controlled study. J Hepatol 38 (2003) 455-460
25. De B.K., Bandyopadhyay K., Das T.K., Das D., Biswas P.K., Majumdar D., et al. Portal pressure response to Losartan compared with propranolol in patients with cirrhosis. Am J Gastroenterol 98 (2003) 1371-1376
26. Arroyo V., Bosch J., Mauri M., Ribera F., Navarro-Lopez F., and Rodes J. Effect of angiotensin II blockade on systemic and hepatic haemodinamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites. Eur J Clin Invest 11 (1981) 221-229
27. Pariente E.A., Bataille C., Bercoff E., and Lebrec D. Acute effects of captopril on systemic and renal haemodynamics and on renal function in cirrhosis patients with ascites. Gastroenterology 88 (1985) 1255-1259
28. Garcia-Tsao G. Angiotensin II receptor antagonists in the pharmacological therapy of portal hypertension: a caution. Letter. Gastroenterology 117 (1999) 740-742
29. Tripathi D., Therapondos G., Lui H.F., Johnston N., Webb D.J., and Hayes P. Chronic administration of Losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis. Am J Gastroenterol 99 (2004) 390-394
30. Weinberg A.J., Zappe D.H., Ashton M., and Weinberg M.S. Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study. Am J Nephrol 24 (2004) 340-345
31. Ostergren J. Candesartan for the treatment of hypertension and heart failure. Expert Opin Pharmacother 5 (2004) 1589-1597
32. Rosei E.A., Rizzoni D., Muiesan M.L., Sleiman I., Salvetti M., Monteduro C., et al. CENTRO ( CandEsartaN on Atherosclerotic Risk factors) study investigators. J Hypertens 23 (2005) 435-444
33. O'Meara F., Lewis E., Granger C., Dunlap M.E., McKelvie R.S., Probstfield J.L., et al. Patient perception of the effect of treatment with Candesartan in heart failure. Results of Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur J Heart Fail 7 (2005) 650-656
34. Kim S., and Iwao H. Involvement of angiotensin II in cardiovascular and renal injury: effects of an AT1 receptor antagonist on gene expression and the cellular phenotype. J Hypertens 15 (1997) S3-S7
35. Otsuka M., Takahashi H., Shiratori M., Chiba H., and Abe S. Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist. Thorax 59 (2004) 31-38
36. Boffa J., Lu Y., Placier S., Stefanski A., Dussaule J.C., and Chatziantoniou C. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 14 (2003) 1132-1144
37. Yamada T., Kuna A., Masuda K., Ogawa K., Sogawa M., Nakamura S., et al. Candesartan, an angiotensin II receptor antagonist; suppresses pancreatic inflamation and fibrosis in rats. J Pharmacol Exp Ther 307 (2003) 17-23
38. Tanabe A., Naruse M., Hara Y., Sato A., Tsuchiya K., Nishikawa T., et al. Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats. J Hypertens 22 (2004) 1017-1023
39. Onishi K., Dohi K., Koji T., Funabiki K., Kitamura T., Imanaka-Yoshida K., Ito M., et al. Candesartan prevent myocardial fibrosis during progression of congestive heart failure. J Cardiovasc Pharmacol 43 (2004) 860-867
40. Tuncer I., Ozbeck H., Ugras S., and Bayram I. Anti fibrogenic effects of Captopril and Candesartan cilexetil on the hepatic fibrosis development in rat. The effect of AT 1 receptor blocker on hepatic fibrosis. Exp Toxicol Pathol 55 (2003) 159-166
41. Nie L., Imamura M., Itoh H., and Ueno H. Pivastatin enhances the antifibrogenesis effects of Candesartan, an angiotensin II receptor blocker, on CCL14 induced liver fibrosis in rats. J UOEH 26 (2004) 165-177
42. McHutchison JG, Blatt L-M, De Medina M, Craig JR, Conrad A, Schiff ER, Tong MJ, and the Consensus Interferon Study Group. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. J Gastroenterol Hepatol 2000;15:945-951.
43. Pares A., Deulofeu R., Gimenez A., Caballeria L., Bruguera M., caballeria J., et al. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and its usefulness as a marker of fibrosis. Hepatology 24 (1996) 1399-1403
44. Patel K., Lajoie A., Heaton S., Pianko S., Beheling C.A., Bylund D., et al. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol 18 (2003) 253-257
45. Saitou Y., Shiraki K., Yamanaka Y., Yamaguchi Y., Kawakita T., Yamamoto N., et al. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40 in patients with HCV associated liver disease. World J Gastroenterol 11 (2005) 476-481
46. Fontana R.J., and Lok A.S. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 36 (2003) S57-S64
47. Bosch J., Mastai R., Kravetz D., Navasa M., and Rodes J. Hemodinamic evaluation of the patients with portal hypertension. Semin Liver Dis 6 (1986) 309-317
48. Castano G., Viudez P., Riccitelli M., and Sookaian S. A randomized study of Losartan vs propranolol: effects on hepatic and systemic hemodynamics in cirrhotic patients. Ann Hepatol 2 (2003) 36-40
49. Garcia-Pagan J.C., Feu F., Bosch J., and Rodes J. Propranolol compared with propranolol plus isosorbide-r-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann Intern Med 114 (1991) 869-873
50. Banares R., Moitinho E., Matilla A., Garcia Pagan J.C., Lampreave J.L., Piera C., et al. Randomised comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology 36 (2002) 1367-1373
51. D'Amico G., Garcia Tsao G., Cales P., Escorsell A., Nevens F., Cestari R., et al. Diagnosis of Portal hypertension: how and when. In: De Franchis R. (Ed). Portal hypertension III. Proceedings of III Baveno international consensus workshop on definition, methodology and therapeutic strategies (2001), Blackwell Science 36-64
52. Groszmann R.J., Bosch J., Grace N.D., Conn H.O., Gracia-Tsao G., Navasa M., et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of first variceal hemorrhage. Gastroent 99 (1990) 1401-1407
53. Feu F., Garcia Pagan J.C., Bosch J., Luca A., Teres J., Escorsell A., et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 346 (1995) 1056-1059
54. Grace N, Garcia-Pagan JC, Albillos A, Angelico M, Boyer JD, Chalasami N, et al. Primary prophilaxis for variceal bleeding. In: De Franchis R editor. Portal Hypertension IV. Proceedings of the Baveno IV international consensus Workshop on methodology of diagnosis and treatment; 2005. pp. 168-200.
55. Groszmann R.J., Garsia-Tsao G., Bosch J., Grace N.D., Burroughs A.K., Planas R., et al. Portal Hypertension Cooperative Group. N Engl J Med 353 (2005) 2254-2261
56. Yokohama S., Yoneda M., Haneda M., et al. Therapeutic efficacy of angiotensin II receptor antagonist in patients with non alcoholic steatohepatitis. Hepatology 40 (2004) 1222-1225
57. Sookoian S., Fernandez M.A., and Castano G. Effects of six months losartan administration on liver fibrosis in chronic hepatitis C: a pilot study. World J Gastroenterol 11 (2005) 7560-7563
58. Sebastiani G., and Alberti A. Non invasive fibrosis biomarkers reduce but do not substitute the need for liver biopsy. World J Gastroenterol 12 (2006) 3682-3694
59. Kropf J., Gressner A.M., and Tittor W. Logistic-regression model for assessing portal hypertension by measuring hyaluronic acid (hyaluronan) and laminin in serum. Clin Chem 37 (1991) 30-35
60. Plebani M., Giacomini A., Floreani A., Chiaramonte M., Soffiati G., Naccarato R., et al. Biochemical markers of hepatic fibrosis in primary biliary cirrhosis. Ric Clin Lab 20 (1990) 269-274
61. Parea A., Deulofeu R., Gimenez A., Caballeria L., Bruguera M., Caballeria J., et al. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. Hepatology 24 (1996) 1399-1403
62. Guechot J., Laudat A., Loria A., Serfaty L., Poupon R., and Gibodeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 42 (1996) 558-563
63. Suzuki A., Angulo P., Lymp J., Li D., Satomura S., and Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non alcoholic fatty liver disease. Liver Int 25 (2005) 779-786
64. Montazeri G., Estakhi A., Mohamadnejad M., Nouri N., Montazeri F., Mohammadkani A., et al. Serum hyaluronate as non invasive marker of hepatic fibrosis and inflammation in HBeAg negative chronic hepatitis B. BMC Gastroenterol 5 (2005) 32
65. Sakugawa H., Nakayoshi T., Kobashigawa K., Yamashiro T., Maeshiro T., Miyagi S., et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with non alcoholic fatty liver disease. World J Gastroenterol 11 (2005) 255-259
66. Nagula S., Jain D., Groszmann R.J., and Garcia-Tsao G. Histological - hemodynamic correlation in cirrhosis- a histological classification of the severity of cirrhosis. J Hepatol 44 (2006) 111-117
67. Blasco A., Forns X., Carrion J.A., Garcia-Pagan J.C., Gilabert R., Rimola A., et al. Hepatic venous pressure gradient identifies at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 43 (2006) 492-499